Published in Nanoscale on January 27, 2014
Nanoparticle biointerfacing by platelet membrane cloaking. Nature (2015) 2.09
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett (2014) 1.55
Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett (2015) 0.97
Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release (2015) 0.83
Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int J Nanomedicine (2015) 0.82
Cell or cell membrane-based drug delivery systems. Theranostics (2015) 0.82
Engineered nanoparticles mimicking cell membranes for toxin neutralization. Adv Drug Deliv Rev (2015) 0.81
Synthesis of Nanogels via Cell Membrane-Templated Polymerization. Small (2015) 0.80
Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics (2016) 0.80
A Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles. Theranostics (2016) 0.78
Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome. Nat Commun (2017) 0.78
Cell membrane-derived nanomaterials for biomedical applications. Biomaterials (2017) 0.76
Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment. Int J Nanomedicine (2017) 0.75
Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes. Theranostics (2017) 0.75
Cell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine Platform. Vaccines (Basel) (2015) 0.75
Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy. Theranostics (2017) 0.75
Bio-inspired nanomedicine strategies for artificial blood components. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
The contribution of sialic acid to the surface charge of the erythrocyte. J Biol Chem (1962) 6.39
Membrane asymmetry. Science (1977) 5.12
Chemistry, metabolism, and biological functions of sialic acids. Adv Carbohydr Chem Biochem (1982) 3.53
Completely "green" synthesis and stabilization of metal nanoparticles. J Am Chem Soc (2003) 3.14
Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol (2009) 2.76
Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci U S A (2011) 2.63
Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science (2013) 2.42
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A (2011) 2.37
Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov (2011) 2.32
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials (2008) 2.21
Topographical distribution of complex carbohydrates in the erythrocyte membrane. J Biol Chem (1974) 2.21
Sialic acids in molecular and cellular interactions. Int Rev Cytol (1997) 1.79
A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol (2013) 1.70
Role of sialic acid in erythrocyte survival. Blood (1975) 1.43
Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci U S A (2009) 1.38
Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis (2010) 1.31
'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale (2013) 1.28
Interaction of nanoparticles with lipid membrane. Nano Lett (2008) 1.26
Biomimetic delivery with micro- and nanoparticles. Adv Mater (2012) 1.25
Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale (2013) 1.20
Erythrocyte-inspired delivery systems. Adv Healthc Mater (2012) 1.20
The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy. Nano Lett (2005) 1.19
Exploring and exploiting chemistry at the cell surface. Nat Chem (2011) 1.09
Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm (2004) 1.08
Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater (2013) 0.97
Simple preparation of nanoparticles coated with carbohydrate-carrying polymers. Biomaterials (1997) 0.97
Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomedicine (Lond) (2013) 0.92
Membranes of animal cells. 8. Distribution of sialic acid, hexosamines and sialidase in the L cell. Biochim Biophys Acta (1971) 0.89
Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale (2013) 0.89
Two types of vesicles from the erythrocyte-ghost membrane differing in surface charge. Separation and characterization by preparative free-flow electrophoresis. Eur J Biochem (1974) 0.86
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A (2011) 2.37
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials (2008) 2.21
Nanoparticle-induced surface reconstruction of phospholipid membranes. Proc Natl Acad Sci U S A (2008) 1.90
Micromachine-enabled capture and isolation of cancer cells in complex media. Angew Chem Int Ed Engl (2011) 1.87
A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol (2013) 1.70
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol (2012) 1.68
Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A (2010) 1.64
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett (2014) 1.55
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52
Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol (2013) 1.50
Retracted Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia. Diagn Pathol (2014) 1.39
Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv (2010) 1.35
Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano (2010) 1.35
Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials (2009) 1.35
Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol (2009) 1.35
Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther (2008) 1.30
'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale (2013) 1.28
Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest Dermatol (2009) 1.23
NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell (2010) 1.22
Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale (2013) 1.20
Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials (2011) 1.20
Erythrocyte-inspired delivery systems. Adv Healthc Mater (2012) 1.20
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One (2011) 1.18
Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc Natl Acad Sci U S A (2012) 1.16
Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm (2010) 1.14
Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir (2010) 1.14
Regulation of Nur77 expression by β-catenin and its mitogenic effect in colon cancer cells. FASEB J (2010) 1.14
Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano (2010) 1.12
Polymeric nanoparticles for drug delivery. Methods Mol Biol (2010) 1.12
Artificial micromotors in the mouse's stomach: a step toward in vivo use of synthetic motors. ACS Nano (2015) 1.11
Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm (2011) 1.11
The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials (2009) 1.10
Rapid delivery of drug carriers propelled and navigated by catalytic nanoshuttles. Small (2010) 1.10
Stimuli-responsive liposome fusion mediated by gold nanoparticles. ACS Nano (2010) 1.10
Lipid- and polymer-based nanostructures for cancer theranostics. Theranostics (2012) 1.09
Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab (2009) 1.08
Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J Am Chem Soc (2011) 1.08
Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids. Biomaterials (2010) 1.08
Cargo-towing fuel-free magnetic nanoswimmers for targeted drug delivery. Small (2011) 1.06
Propionibacterium acnes CAMP factor and host acid sphingomyelinase contribute to bacterial virulence: potential targets for inflammatory acne treatment. PLoS One (2011) 1.04
Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small (2010) 1.04
HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem (2008) 1.03
Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett (2015) 0.97
Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater (2013) 0.97
Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharm (2012) 0.97
Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: the eye. Cell Mol Life Sci (2011) 0.96
Methods to track single-molecule trajectories. Langmuir (2006) 0.93
Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomedicine (Lond) (2013) 0.92
An innate bactericidal oleic acid effective against skin infection of methicillin-resistant Staphylococcus aureus: a therapy concordant with evolutionary medicine. J Microbiol Biotechnol (2011) 0.89
Hydrogel containing nanoparticle-stabilized liposomes for topical antimicrobial delivery. ACS Nano (2014) 0.89
Magnetic field activated lipid-polymer hybrid nanoparticles for stimuli-responsive drug release. Acta Biomater (2012) 0.89
Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin Biol Ther (2012) 0.89
Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale (2013) 0.89
Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice. PLoS One (2010) 0.89
Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One (2008) 0.88
Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater Sci (2015) 0.87
In vivo clearance and toxicity of monodisperse iron oxide nanocrystals. ACS Nano (2012) 0.87
Real-time electrochemical monitoring of drug release from therapeutic nanoparticles. J Control Release (2009) 0.87
Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display. Biomaterials (2011) 0.87
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine (Lond) (2010) 0.87
Nanoparticle-stabilized liposomes for pH-responsive gastric drug delivery. Langmuir (2013) 0.86
Large-scale synthesis of lipid-polymer hybrid nanoparticles using a multi-inlet vortex reactor. Langmuir (2012) 0.84
Nanoparticle approaches against bacterial infections. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.83
Multifunctional nanoparticles for prostate cancer therapy. Expert Rev Anticancer Ther (2009) 0.82
Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces (2014) 0.81
Inhibition of VDAC1 prevents Ca²⁺-mediated oxidative stress and apoptosis induced by 5-aminolevulinic acid mediated sonodynamic therapy in THP-1 macrophages. Apoptosis (2014) 0.81
Turning erythrocytes into functional micromotors. ACS Nano (2014) 0.81
Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered poly(ethylene glycol) shedding. Langmuir (2011) 0.80
Phylogenetic study of Oryzoideae species and related taxa of the Poaceae based on atpB-rbcL and ndhF DNA sequences. Mol Biol Rep (2011) 0.80